

1. Which is a drug approval process for new medications that have minor improvements over current therapies?

- a. Standard pathway
- b. Accelerated pathway
- c. Fast track pathway
- d. Breakthrough pathway

2. In a priority review, the FDA's goal is to take action on the application in _____ months.

- a. 2 months
- b. 12 months
- c. 6 months
- d. 3 months

3. Which of the following is NOT a common risk factor for developing prostate cancer?

- a. Age
- b. Smoking
- c. Race
- d. Family history

4. In most cases, which of the following is a sign/symptom in the early development of prostate cancer?

- a. Back pain
- b. Change in urinary frequency
- c. Lower extremity edema
- d. Early stages are usually asymptomatic

5. Which of the following is the mechanism of action of Erleada?

- a. Blocking the production of testosterone
- b. Blocking androgen receptors
- c. Directly attacking the tumor causing cell death
- d. Alkylating the cell's DNA preventing reproduction

6. Breast cancer only occurs in women (true or false)

- a. True
- b. False

7. A 40-year-old woman at average risk for breast cancer should have a clinical breast examination by a healthcare professional how often?

- a. Every 6 months
- b. Every year
- c. Every 3 years
- d. Every 5 years

8. A breast cancer patient has a treatment regimen consisting of chemotherapy, anti-HER2 therapy, and endocrine therapy. Which of the following best describes her type of breast cancer?

- a. HR +, HER2 +
- b. HR +, HER2 -
- c. HR -, HER2 +
- d. HR -, HER2 -

9. What new breast cancer medication is indicated for the treatment of HER2 negative, HR positive, postmenopausal women with metastatic or advanced breast cancer in combination with an aromatase inhibitor for initial endocrine based treatment?

- a. Nerlynx (neratinib)
- b. Kisqali (ribociclib)
- c. Verzenio (abemaciclib)
- d. Calquence (acalabrutnib)

10. Which new breast cancer medication requires antidiarrheal prophylaxis with loperamide for the first 2 months of treatment?

- a. Nerlynx (neratinib)
- b. Kisqali (ribociclib)
- c. Verzenio (abemaciclib)
- d. Aliqopa (copanlisib)

11. Blood cancers originate from which of the following?

- a. Vasculature
- b. Bone Marrow
- c. Spleen
- d. Liver

12. Leukemia chemotherapy treatment typically involves a three-phase process. Which choice below correctly describe this process?

- a. Induction phase, consolidation phase, and maintenance phase
- b. Treatment phase, remission phase, and post-remission phase
- c. Primary chemotherapy phase, secondary chemotherapy phase, and final chemotherapy phase

13. What is the indication for the new FDA approved agent IDHIFA (enasidenib)?

- a. For the treatment of newly diagnosed AML who have FLT3 gene mutation.
 - b. For the treatment of relapsed or refractory B-cell AML.
 - c. For adults with relapsed or refractory AML with a isocitrate dehydrogenase-2 (IDH2) mutation.
-

14. Which medication below has an FDA black box warning for differentiation syndrome?

- a. Rydapt
- b. IDHIFA
- c. Besponsa
- d. Calquence

15. Hodgkin's lymphoma is based on the presence of Reed-Sternberg cells (true or false):

- a. True
 - b. False
-

Participant Information:

AL License # _____

Name _____

Address _____

City _____ State _____ Zip _____

E-mail _____

NABP e-Profile # _____

MM/DD (month/day of birth) _____

How long did it take you to read the article and complete this test?
 _____ hours _____ minutes

My signature certifies that I have independently taken this CE examination.

CE Assessment Answers				
Please circle your answers (one answer per question)				
1.	A	B	C	D
2.	A	B	C	D
3.	A	B	C	D
4.	A	B	C	D
5.	A	B	C	D
6.	A	B		
7.	A	B	C	D
8.	A	B	C	D
9.	A	B	C	D
10.	A	B	C	D
11.	A	B	C	D
12.	A	B	C	
13.	A	B	C	
14.	A	B	C	D
15.	A	B		

Program Evaluation – Must be completed for credit.

Please rate the following items on a scale from 1 (poor) to 4 (excellent).

- 1. Overall quality of the article 1 2 3 4
- 2. Relevance to pharmacy practice 1 2 3 4
- 3. Value of the content 1 2 3 4

Please answer each question, marking whether you agree or disagree.

- 4. This course met the learning objectives. Agree Disagree
- 5. The article did not promote a particular product or company. Yes No

Impact of the Activity

The information presented (check all that apply):

- 6. Reinforced my current practice/treatment habits Will improve my practice/patient outcomes
 Provided new ideas or information I expect to use Adds to my knowledge
- 7. Will the information presented cause you to make any changes in how you do your job? Yes No
- 8. How committed are you to making these changes?
 (Not committed) 1 2 3 4 (Very committed).
- 9. Do you feel future activities on this subject matter are necessary and/or important? Yes No

Follow-Up

As part of our ongoing quality-improvement effort, we would like to be able to contact you in the event we conduct a follow-up survey to assess the impact of our educational interventions on professional practice. Are you willing to participate in such a survey?

- Yes No



The Alabama Pharmacy Association Research and Education Foundation is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.